ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, and clinical development. 
Type
Public
HQ
Westminster, US
Founded
2009
Size (employees)
20 (est)
ARCA biopharma was founded in 2009 and is headquartered in Westminster, US
Report incorrect company information

ARCA biopharma Office Locations

ARCA biopharma has offices in Westminster and Aurora
Westminster, US (HQ)
140 11080 Circle Point Rd
Aurora, US
12635 E. Montview Blvd
Westminster, US
11080 CirclePoint Rd Ste 140
Show all (3)
Report incorrect company information

ARCA biopharma Financials and Metrics

ARCA biopharma Revenue

USD

Net income (Q1, 2018)

(2.7 m)

EBIT (Q1, 2018)

(2.8 m)

Market capitalization (18-Jul-2018)

8.1 m

Closing share price (18-Jul-2018)

0.6

Cash (31-Mar-2018)

12.1 m
ARCA biopharma's current market capitalization is $8.1 m.
Annual
USDFY, 2016FY, 2017

General and administrative expense

4.6 m

R&D expense

14.1 m

Operating expense total

18.7 m

EBIT

(18.7 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

General and administrative expense

1 m950 k1.1 m

R&D expense

1.4 m1.3 m1.7 m

Operating expense total

2.4 m2.3 m2.8 m

EBIT

(2.4 m)(2.3 m)(2.8 m)
Annual
USDFY, 2016FY, 2017

Cash

7.4 m8.7 m

Current Assets

21.4 m12.3 m

PP&E

66 k42 k

Total Assets

24.6 m12.4 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

19.4 m17.2 m12.2 m44.1 m41.5 m29.7 m14.4 m8.1 m6.2 m12.1 m

Current Assets

19.7 m17.5 m12.7 m44.3 m41.7 m31 m26.7 m23.8 m19.9 m12.7 m

PP&E

29 k26 k34 k34 k31 k24 k76 k69 k59 k37 k

Total Assets

20.5 m18 m13.3 m45.1 m42.4 m36.9 m32.6 m28.7 m20.6 m12.8 m
Annual
USDFY, 2016FY, 2017

Net Income

(16.4 m)(18.5 m)

Depreciation and Amortization

24 k27 k

Accounts Payable

841 k(583 k)

Cash From Operating Activities

(15 m)(17.5 m)
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(4.8 m)(7.1 m)(2.7 m)(5.5 m)(8.3 m)(3.6 m)(7.5 m)(12.2 m)(4.3 m)(2.7 m)

Depreciation and Amortization

5 k8 k4 k9 k14 k5 k9 k17 k7 k6 k

Accounts Payable

128 k(232 k)(144 k)(198 k)(167 k)380 k391 k648 k(234 k)(14 k)

Cash From Operating Activities

(5.5 m)(7.5 m)(3.1 m)(5.5 m)(7.9 m)(3.9 m)(7.4 m)(11.1 m)(4.3 m)(3.1 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

ARCA biopharma Company Life and Culture

Report incorrect company information